Dermatologic Therapy

Article	Citations
Cutaneous signs in COVID ‐19 patients: A review	152
Oral manifestations ofCOVID‐19 disease: A review article	137
Consensus of Chinese experts on protection of skin and mucous membrane barrier for health‐care workers fighting against coronavirus disease 2019	117
COVID ‐19 and economy	106
Cutaneous manifestations and considerations in COVID ‐19 pandemic: A systematic review	76
Biologics increase the risk of SARS ‐ CoV ‐2 infection and hospitalization, but not ICU admissi	74
Herpes zoster might be an indicator for latent COVID 19 infection	61
Increased flare of acne caused by long‐time mask wearing during COVID ‐19 pandemic among general population	59
COVID‐19 related masks increase severity of both acne (maskne) and rosacea (mask rosacea): Multi‐center, real‐life, telemedical, and observational prospective study	59
The potential of probiotics for treating acne vulgaris: A review of literature on acne and microbiota	55
The clinics of HHV ‐6 infection in COVID ‐19 pandemic: Pityriasis rosea and Kawasaki disease	53
Inconveniences due to the use of face masks during the COVID ‐19 pandemic: A survey study of 876 young people	52
COVID‐19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action	49
Challenges of COVID‐19 pandemic for dermatology	49
A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID ‐19: Will cases of psoriasis increase after COV	47
The effect of the “stay‐at‐home” policy on requests for dermatology outpatient clinic visits after the COVID ‐19 outbreak	47
Evaluation of skin problems and dermatology life quality index in health care workers who use personal protection measures during COVID ‐19 pandemic	47
Cutaneous sıde‐effects of the potential COVID‐19 drugs	46
Cutaneous manifestations in hospitalized patients diagnosed as COVID ‐19	46
What does androgenetic alopecia have to do with COVID‐19? An insight into a potential new therapy	46
Back to the basics: Propolis and COVID ‐19	45
Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine	44
Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti‐ interleukin ‐17 treatment: A real‐life 52‐week retrospective study	42
Relative changes in the pattern of diseases presenting in dermatology outpatient clinic in the era of theCOVID‐19 pandemic	42
Telogen effluvium associated with COVID‐19 infection	41

Unraveling the mystery of Covid‐19 cytokine storm: From skin to organ systems	41
Cutaneous manifestations of the Coronavirus Disease 2019 ( COVID ‐19): A brief review	40
COVID‐19 knowledge prevents biologics discontinuation: Data from an Italian multicenter survey duringRED‐ZONEdeclaration	39
Covid‐19 and exacerbation of psoriasis	39
Urticaria and COVID ‐19: A review	38
Risankizumab treatment in psoriasis patients who failed anti‐IL17: A 52‐week real‐life study	38
Maculopapular eruptions associated to COVID ‐19: A subanalysis of the COVID‐Piel study	38
Efficacy and safety of risankizumab in psoriasis patients who failed anti‐IL ‐17, anti‐12/23 and/or anti IL ‐23: Preliminary data	37
Cutaneous adverse reactions after COVID ‐19 vaccines in a cohort of 2740 Italian subjects: An observational study	37
Formulation, optimization, and in vitro evaluation of nanostructured lipid carriers for topical delivery of Apremilast	36
The top 10 cosmeceuticals for facial hyperpigmentation	36
The impact of air pollution on skin and related disorders: A comprehensive review	36
Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during theCOVID‐19 pandemic	36
Psychodermatology of vitiligo: Psychological impact and consequences	35
Comparative analysis of perceived stress in dermatologists and other physicians during national lock‐down and COVID ‐19 pandemic with exploration of possible risk fa	33
Real‐life experience of guselkumab in patients with psoriasis	33
Dupilumab and COVID ‐19: What should we expect?	33
Novel coronavirus disease 2019 (COVID‐19) and neurodegenerative disorders	33
Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study	32
Drug survival in the treatment of generalized pustular psoriasis: A retrospective multicenter study	32
Treatment of COVID ‐19 with pentoxifylline: Could it be a potential adjuvant therapy?	32
Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate‐to‐severe atopic dermatitis: A network meta‐analysis	32
Evaluation of the effects of COVID‐19 pandemic on hair diseases through a web‐based questionnaire	32
Upadacitinib improved alopecia areata in a patient with atopic dermatitis: A case report	31
Mucosal involvement in a COVID ‐19‐positive patient: A case report	31
COVID ‐19 vaccine‐induced urticarial vasculitis	31
Psoriasis flare after influenza vaccination in Covid‐19 era: A report of four cases from a single center	31
Herpes zoster as a potential complication of coronavirus disease 2019	31
Ixekizumab: An efficacious treatment for both psoriasis and hidradenitis suppurativa	31
Teledermatologic monitoring for chronic cutaneous autoimmune diseases with smartworking during COVID‐19 emergency in a tertiary center in Italy	31
Internet and social media use in dermatology patients: Search behavior and impact on patient‐physician relationship	31
Teledermatology and chronic skin diseases: Real life experience in a Southern Italian Dermatologic Centre	30
COVID‐19 and psoriasis: Should we fear for patients treated with biologics?	30
Gender differences in cutaneous melanoma: Demographics, prognostic factors, and survival outcomes	29
Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine	29
Are erythema multiforme and urticaria related to a better outcome of COVID ‐19?	29
Chilblain‐like lesions in pediatrics dermatological outpatients during the COVID ‐19 outbreak	29
Autologous platelet‐rich fibrin injections in the management of facial cutaneous sinus tracts secondary to medication‐related oste	29
Possible association between IgA vasculitis and COVID ‐19	29
Efficacy of resveratrol in the wound healing process by reducing oxidative stress and promoting fibroblast cell proliferation and migration	29
Onset of vitiligo in a psoriasis patient on ixekizumab	29
Priorities for global health community in COVID ‐19 pandemic	29
COVID‐19 with dermatologic manifestations and implications: An unfolding conundrum	28
Tildrakizumab for the treatment of moderate to severe psoriasis: Results from a single center preliminary real‐life study	28
Angiotensin II receptors: Impact for COVID ‐19 severity	28
The use of face masks during the COVID ‐19 pandemic in Poland: A survey study of 2315 young adults	28
Emerging role of anti‐IL23 in the treatment of psoriasis: When humanized is very promising	28
SARS CoV‐2 aggravates cellular metabolism mediated complications inCOVID‐19 infection	27
Emerging role of nanocarriers based topical delivery of anti‐fungal agents in combating growing fungal infections	27
COVID ‐19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain	27

Solidarity and transparency against the COVID ‐19 pandemic	27
Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting	27
COVID ‐19 from the perspective of dentists: A case report and brief review of more than 170 cases	27
Sudden onset of vitiligo after COVID‐19 vaccine	27
Aphthous stomatitis in COVID ‐19 patients: Case‐series and literature review	26
New‐onset lichen planus arising after COVID‐19 vaccination	26
A systematic review on mucocutaneous presentations after COVID‐19 vaccination and expert recommendations about vaccination of important immune‐mediated dermatologic disorders	26
COVID ‐19 and exacerbation of dermatological diseases: A review of the available literature	26
Collision tumors: A review of their types, pathogenesis, and diagnostic challenges	26
Dermatological manifestation of pediatrics multisystem inflammatory syndrome associated with COVID ‐19 in a 3‐year‐old girl	26
Doxycycline, a widely used antibiotic in dermatology with a possible anti‐inflammatory action against IL ‐6 in COVID ‐19 outbreak	26
Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?	26
5‐Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety	26
JAK‐inhibitors for dermatomyositis: A concise literature review	25
Subacute cutaneous lupus erythematosus flare triggered by COVID ‐19 vaccine	25
Chemical and mechanical characterization of hyaluronic acid hydrogel cross‐linked with polyethylen glycol and its use in dermatology	25
Telogen effluvium related to post severe Sars‐Cov‐2 infection: Clinical aspects and our management experience	25
Tumor necrosis factor inhibitors are associated with a decreased risk ofCOVID‐19‐associated hospitalization in patients with psoriasis—A population‐based cohort study	25
Increased risk of late‐onset, immune‐mediated, adverse reactions related to dermal fillers in patients bearing HLA‐B *08 and DRB1	25
Analysis of dermatologic conditions in Turkey and Italy by using Google Trends analysis in the era of the COVID ‐19 pandemic	25
Cause and management of lipedema‐associated pain	25
Management of urticaria in COVID ‐19 patients: A systematic review	25
Safety of low‐dose oral minoxidil treatment for hair loss. A systematic review and pooled‐analysis of individual patient data	25
Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry	25
Management of telogen effluvium during the COVID‐19 emergency: Psychological implications	25
Photodynamic therapy in dermatology: Beyond current indications	25
Evaluation of dermatology consultations in the era of COVID‐19	25
Effectiveness of anti‐interleukin 23 biologic drugs in psoriasis patients who failed anti‐interleukin 17 regimens. A real‐life experience	25
Exacerbation of plaque psoriasis after inactivated and BNT162b2 mRNA COVID ‐19 vaccines: A report of two cases	24
SARS‐CoV‐2 as possible inducer of viral reactivations	24
Mask‐induced Koebner phenomenon and its clinical phenotypes: A multicenter, real‐life study focusing on 873 dermatological consultations during COVID‐19 pandemics	24
Guselkumab: Mid‐term effectiveness, drug survival, and safety in real clinical practice	24
The use of human acellular dermal matrices in advanced wound healing and surgical procedures: State of the art	24
Efficacy and safety of oral minoxidil in female androgenetic alopecia	24
The explosion in scabies cases during COVID ‐19 pandemic	23
Onset/flare of psoriasis following the ChAdOx1 nCoV ‐19 Corona virus vaccine ( Oxford‐AstraZeneca /Covishield): Report of two case	23
Facial vascular danger zones for filler injections	23
COVID ‐19 and SARS : Differences and similarities	23
Dermatological diseases presented before COVID ‐19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID	23
Psychodermatological mechanisms of psoriasis	23
Pulsed dye laser followed by intradermal botulinum toxin type‐A in the treatment of rosacea‐associated erythema and flushing	23
Multicenter study evaluating the impact of COVID ‐19 outbreak on dermatology outpatients in Turkey	23
Psoriasis andCOVID‐19: A narrative review with treatment considerations	22
Systematic review of platelet‐rich plasma in treating alopecia: Focusing on efficacy, safety, and therapeutic durability	22
Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 nCoV ‐19 corona virus vaccine (recombinant)	22
Anti‐IL17 and anti‐IL23 biologic drugs for scalp psoriasis: A single‐center retrospective comparative study	22
Sweet syndrome afterOxford‐AstraZeneca COVID‐19 vaccine (AZD1222) in an elderly female	22
Progression of mycosis fungoides after treatment with dupilumab: A case report	22
Psychodermatology of skin picking (excoriation disorder): A comprehensive review	22
Luliconazole‐loaded nanostructured lipid carriers for topical treatment of superficial Tinea infections	22
Cutaneous adverse events related to COVID ‐19 vaccines: A cross‐sectional questionnaire‐based study of 867 patients	22
Cutaneous manifestations following COVID‐19 vaccination: A report of 25 cases	22
COVID ‐19 induced telogen effluvium	22
Impact on health‐related quality of life and symptoms of anxiety and depression after 32 weeks of Dupilumab treatment for moderate‐to‐severe atopic dermatitis	22
Topical treatment for plantar warts: A systematic review	22
“Covid arm”: Abnormal side effect after Moderna COVID ‐19 vaccine	22
Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis	22
Will teledermatology be the silver lining during and afterCOVID‐19?	22
COVID‐19 and impact of personal protective equipment use: From occupational to generalized skin care need	22
Evaluating hyaluronic acid dermal fillers: A critique of current characterization methods	21
COVID vaccination in patients under treatment with rituximab: A presentation of two cases from Iran and a review of the current knowledge with a specific focus on pemphigus	21
Comprehensive overview of COVID ‐19 based on current evidence	21
Cutaneous adverse reactions of COVID ‐19 vaccines: A systematic review	21
Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16‐week real‐life experience during the COVID ‐19 pandemic in Italy	21
What the physicians should know about mast cells, dendritic cells, urticaria, and omalizumab duringCOVID‐19 or asymptomatic infections due toSARS‐CoV‐2?	21
New emergent therapies for atopic dermatitis: A review of safety profile with respect to female fertility, pregnancy, and breastfeeding	20
The manifestation of oral mucositis in COVID ‐19 patients: A case‐series	20
SARS‐CoV‐2 vaccination‐induced cutaneous vasculitis: Report of two new cases and literature review	20
Systematic review of low‐dose isotretinoin for treatment of acne vulgaris: Focus on indication, dosage, regimen, efficacy, safety, satisfaction, and follow up, based on clinical studies	20
The efficacy of energy‐based devices combination therapy for melasma	20
Cutaneous manifestations of COVID ‐19: A review of the published literature	20
Micro needling: A novel therapeutic approach for androgenetic alopecia, A Review of Literature	20
Recurrent aphthous stomatitis: A comprehensive review and recommendations on therapeutic options	20
Brodalumab: A new way to inhibit IL ‐17 in psoriasis	20
An overview of treatment options for mild‐to‐moderate acne based on American Academy of Dermatology, European Academy of Dermatology and Venereology, and Italian Society of Dermatology and Venereology	20
The use of guselkumab 100 mg every 4 weeks on patients with hidradenitis suppurativa and a literature review	20
Pityriasis rosea after Moderna mRNA ‐1273 vaccine: A case series	20
Contact dermatitis due to masks and respirators during COVID ‐19 pandemic: What we should know and what we should do	20
Surveillance of psoriatic patients on biologic treatment during the COVID‐19 pandemic: A single‐center experience	20
Acute generalized exanthematous pustulosis after COVID ‐19 treatment with hydroxychloroquine	20

Janus kinase inhibitors for treatment of morphea and systemic sclerosis: A literature review	20
Pityriasis rosea‐like cutaneous eruption as a possible dermatological manifestation afterOxford‐AstraZenecavaccine: Case report and brief literature review	20
Patients with specific skin disorders who are affected by COVID ‐19: What do experiences say about management strategies? A systematic review	20
Scabies: A comprehensive review and current perspectives	20
Changing paradigms of dermatology practice in developing nations in the shadow of COVID ‐19: Lessons learnt from the pandemic	20
New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection	19
Alopecia areata in a COVID‐19 patient: A case report	19
Maculopapular skin eruptions associated with Covid‐19: A systematic review	19
Change of the diagnostic distribution in applicants to dermatology after COVID ‐19 pandemic: What it whispers to us?	19
A systematic review on treatment‐related mucocutaneous reactions in COVID ‐19 patients	19
The effectiveness of combination therapies for androgenetic alopecia: A systematic review and meta‐analysis	19
Isotretinoin and the eye: A review for the dermatologist	19
Challenges in sarcoidosis and sarcoid‐like reactions associated to immune checkpoint inhibitors: A narrative review apropos of a case	19
Coronavirus‐days ın dermatology	19
Exacerbation of psoriasis following COVID ‐19 vaccination in a patient previously treated with PD ‐1 inhibitor	18
Lichen planus and lichen planopilaris flare after COVID ‐19 vaccination	18
Diagnostic and prognostic values of cutaneous manifestations in COVID ‐19	18
Tetracyclines in COVID ‐19 patients quarantined at home: Literature evidence supporting real‐world data from a multicenter observa	18
Cutaneous manifestations in COVID ‐19: A skin rash in a child	18
Apremilast in dermatology: A review of literature	18
Treatments for alopecia areata: A systematic review and network meta‐analysis	18
Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight in the COVID‐19 era	18
Skin changes attributed to protective measures againstCOVID‐19: A compilation	18
A significant reduction in the diagnosis of melanoma during the COVID‐19 lockdown in a third‐level center in the Northern Italy	18
Guselkumab: Short‐term effectiveness and safety in real clinical practice	18
Laser tattoo removal: Fundamental principles and practical approach	17
Hidden threat lurking behind the alcohol sanitizers in COVID ‐19 outbreak	17
Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors	17
Post Covid‐19 vaccination papulovesicular pityriasis rosea‐like eruption in a young male	17
A fatal case of COVID ‐19 infection presenting with an erythema multiforme‐like eruption and fever	17
Generalized pustular psoriasis following COVID ‐19	17
Itch in the era of COVID‐19 pandemic: An unfolding scenario	17
A daily regimen of a ceramide‐dominant moisturizing cream and cleanser restores the skin permeability barrier in adults with moderate eczema: A randomized trial	17
Familial clustering of COVID ‐19 skin manifestations	17
Azithromycin and COVID‐19: Prompt early use at first signs of this infection in adults and children, an approach worthy of consideration	17
The impact of COVID ‐19 in patients with psoriasis: A multicenter study in Istanbul	17
Management of psychocutaneous disorders: A practical approach for dermatologists	17
Disease progression and comorbidities in lipedema patients: A 10‐year retrospective analysis	16
Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID ‐19 pandemic: A single‐center real‐life experience	16
Dupilumab for the treatment of pembrolizumab‐induced bullous pemphigoid: A case report	16
Platelet‐rich plasma—Where do we stand today? A critical narrative review and analysis	16
Cyclosporin in dermatology: A practical compendium	16
Topical beta‐blockers in dermatologic therapy	16
Pustular psoriasis exacerbated by COVID ‐19 in a patient with the history of psoriasis	16
Safety of SARS‐CoV‐2 vaccines in psoriatic patients treated with biologics: A real life experience	16
Activation of Janus kinase signaling pathway in acne lesions	16
Emerging trends in nanomedicine for topical delivery in skin disorders: Current and translational approaches	16
Transverse leukonychia (Mees' lines) nail alterations in a COVID ‐19 patient	16
Cutaneous lymphocytic vasculitis after administration of COVID ‐19 mRNA vaccine	16
Acne treatment review and future perspectives	16
The efficacy of fractional CO 2 laser in acne scar treatment: A meta‐analysis	16
Effectiveness and safety of guselkumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group	16
Multiple cycles of rituximab therapy for pemphigus: A group of patients with difficult‐ to‐treat disease or a consequence of late rituximab initiation?	16
Cutaneous and histopathological features of coronavirus disease 2019 in pediatrics: A review article	16
Non‐complicated evolution of COVID ‐19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab	16
Merkel cell carcinoma: An updated review of pathogenesis, diagnosis, and treatment options	16
Omalizumab in children and adolescents with chronic spontaneous urticaria: Case series and review of the literature	16
NB‐UVB plus oral Polypodium leucotomos extract display higher efficacy than NB‐UVB alone in patients with vitiligo	16
Immunosuppressive drugs for patients with psoriasis during the COVID ‐19 pandemic era. A review	16
Influence of COVID ‐19 pandemic on hospitalizations at the tertiary dermatology department in south‐west Poland	16
Microneedling in vitiligo: A systematic review	16
Female pattern hair loss: A comprehensive review	16
Dermoscopy as a useful tool for evaluating melasma and assessing the response to 1064‐nm Q‐switched Nd: YAG laser	15
Certolizumab pegol for hidradenitis suppurativa: Case report and literature review	15
Dupilumab induces a rapid decrease of pruritus in adolescents: A pilot real‐life study	15
The clinical utility of teledermoscopy in the era of telemedicine	15
Serum zinc levels and efficacy of zinc treatment in acne vulgaris: A systematic review and meta‐analysis	15
High‐sensitivity C‐reactive protein as a biomarker in detecting subclinical atherosclerosis in psoriasis	15
Different hair loss patterns in two pediatric patients with COVID‐19‐associated multisystem inflammatory syndrome in children	15
Cross sectional quality of life assessment in patients with androgenetic alopecia	15
Patient‐reported outcomes of topical therapies in actinic keratosis: A systematic review	15
PG‐TIME : A practical approach to the clinical management of pyoderma gangrenosum	15
Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases	15
Topical and oral minoxidil for hair disorders in pediatric patients: What do we know so far?	15
Dermatological findings in patients admitting to dermatology clinic after using face masks during Covid‐19 pandemia: A new health problem	15
An updated review of the sebaceous gland and its role in health and diseases Part 1: Embryology, evolution, structure, and function of sebaceous glands	15
Tapinarof for the treatment of psoriasis	15
Efficacy and safety of Risankizumab in moderate to severe psoriasis: A systematic review and meta‐analysis	15
Alopecia areata as an immune‐related adverse event of immune checkpoint inhibitors: A review	15
Alopecia areata in a patient with SARS‐Cov ‐2 infection	15
Acute localized exanthematous pustulosis: Clinical features, pathophysiology, and therapy	15
Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate‐to‐severe psoriasis after 1 year of treatment: Real‐world practice	15
Livedoid vasculopathy in 75 Brazilian patients in a single‐center institution: Clinical, histopathological and therapy evaluation	15
Risankizumab shows high efficacy and maintenance in improvement of response until week 52	15
Antipsoriatic treatments during COVID ‐19 outbreak	15
IL‐17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review	14
Propranolol for infantile hemangioma: Evaluating efficacy and predictors of response and rebound growth	14
Treatment of the tear trough and infraorbital hollow with hyaluronic acid fillers using both needle and cannula	14
Does therapy with biological drugs influence COVID ‐19 infection? Observational monocentric prevalence study on the clinical and epidemiological data of psoriatic pa	14
Aggressive course of pemphigus vulgaris followingCOVID‐19 infection	14
Sequential paradoxical psoriasiform reaction and sacroiliitis following adalimumab treatment of hidradenitis suppurativa, successfully treated with guselkumab	14
Bullous pemphigoid triggered by COVID ‐19 vaccine: Rapid resolution with corticosteroid therapy	14
Telemedicine approach for psoriasis management, time for application? A systematic review of published studies	14
Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review	14
Topical antibiotics in the dermatological clinical practice: Indications, efficacy, and adverse effects	14